Regeneron

Nos guía la excelencia científica y su aplicación en oncología. En el marco de #ESMO26, Alejandro Villapalos, Country Manager de Oncología y Hematología en Regeneron España, comparte su visión sobre el compromiso de Regeneron con una investigación oncológica innovadora y de alcance global.

Some jobs ask you to solve problems. At Regeneron, we have chosen to undertake one of the most difficult and humbling endeavors humankind can pursue: creating new medicines — for patients and families who are counting on us, often when they’ve run out of options. It's science taken seriously, not as a buzzword. It's curiosity that's not only encouraged but expected. And it's a community where people show up, share what they know, and push each other to do better work. This is what a career here actually feels like. #Regeneron #LifeSciences #Biotech #Pharma #ClinicalResearch #CareersInScience #Hiring

Our new paper in Nature highlights how human genetics can help uncover potential new therapeutic strategies for obesity, metabolic dysfunction-associated steatotic liver disease (MASLD) and broader cardiometabolic disease. 💡 Regeneron Genetics Center researchers combined exome data from more than one million people with studies in human liver cells and animal models to investigate the FNIP1 pathway's role in energy metabolism. The findings identify the pathway as a potential therapeutic target and demonstrate how large-scale human genetics can help prioritize new approaches to disease.

Wissenschaft in Fortschritt verwandeln – das ist unsere Mission bei Regeneron für Menschen, die von Krebs betroffen sind. Anlässlich des heutigen #WorldLungCancerDay teilt Dr. med. Steffen Hartrampf, Head und Executive Medical Director International, Onkologie, seine Einblicke mit uns: Erfahren Sie, wie wir bei Regeneron mit Leidenschaft und Innovation neue Behandlungsoptionen voranbringen.

At STAT Breakthrough Summit East, leaders explored what it takes to move from scientific possibility to impact, with an emphasis on the data foundations behind innovation. Gonçalo Abecasis, Regeneron Genetics Center’s SVP and Chief Genomics and Data Science Officer, joined STAT’s Damian Garde to discuss AI-driven genomic research and how data quality and scale can be more influential than model choice. Thank you to STAT and to everyone who made this event energizing and insightful.

RGC to provide in-kind whole exome sequencing in exchange for de-identified biospecimens and de-identified phenotype data. By sequencing and analyzing 540,000 exomes, RGC found rare CIDEB gene mutations linked to a 53% lower risk of MASH. Your cohort could power the next finding.